Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease. Akebia's lead product candidate, AKB-6548, is in a Phase 2b clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. AKB-6548 is being developed as a once-daily oral therapy which works through the inhibition of hypoxia-inducible factor prolyl hydroxylase, leading to stabilization and increased levels of HIFα and therefore improved production of hemoglobin and red blood cells.
Company Growth (employees)
Cambridge, US
Size (employees)
90 (est)+43%
Akebia Therapeutics was founded in 2007 and is headquartered in Cambridge, US

Akebia Therapeutics Office Locations

Akebia Therapeutics has an office in Cambridge
Cambridge, US (HQ)
1100 245 First St

Akebia Therapeutics Data and Metrics

Akebia Therapeutics Financial Metrics

Numbers are in $, USD

Net income (FY, 2016)

(135.7 m)

EBIT (FY, 2016)

(136.5 m)

Market capitalization (25-May-2017)

253.5 m

Closing share price (25-May-2017)


Cash (31-Dec-2016)

187.3 m
Akebia Therapeutics's current market capitalization is $253.5 m.
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

R&D expense

25.4 m43 m115.8 m

General and administrative expense

12.5 m18.5 m22.2 m

Operating expense total

37.9 m61.5 m138 m


(37.9 m)(61.5 m)(136.5 m)

Interest expense

206 k510 k

Interest income

206 k510 k901 k

Net Income

(37 m)(60.7 m)(135.7 m)
Numbers are in $, USDFY, 2014FY, 2015FY, 2016


32.8 m49.8 m187.3 m

Accounts Receivable

48 k


1.5 m2.6 m2.2 m

Current Assets

110.5 m141 m296.3 m


209.9 k540 k2.6 m

Total Assets

111 m142.9 m300.2 m

Accounts Payable

2 m2.3 m2 m

Current Liabilities

6.9 m11.9 m114.3 m

Additional Paid-in Capital

205 m292.8 m365.3 m

Retained Earnings

(100.7 m)(161.4 m)(297.1 m)

Total Equity

104.1 m131 m68.1 m

Financial Leverage

1.1 x1.1 x4.4 x
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Net Income

(37 m)(60.7 m)(135.7 m)

Depreciation and Amortization

49.4 k96 k296 k

Accounts Receivable

87 k


(773 k)(1 m)428 k

Accounts Payable

4.1 m231 k(274 k)

Cash From Operating Activities

(27.5 m)(52.4 m)57.9 m

Purchases of PP&E

(229 k)(414 k)(2.7 m)

Cash From Investing Activities

(65.4 m)(13.7 m)12.7 m

Cash From Financing Activities

104.4 m83.1 m66.9 m
Y, 2016

Financial Leverage

4.4 x

Akebia Therapeutics Market Value History

Akebia Therapeutics Job Categories

Akebia Therapeutics Online and Social Media Presence

Akebia Therapeutics Company Life and Culture

You may also be interested in